Ultomiris 300 & 1100 Mg 300 mg, 1100 mg Concentrate for solution for infusion
PDF Leaflet Revision Date: Not applicable
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of PNH, aHUS, gMG, and NMOSD.
Dosage (summary)
Weight-based dosing every 4 or 8 weeks after loading dose.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use contraception during treatment; unknown if excreted in milk.
Key Drug Interactions
- Neonatal Fc receptor blockers
Contraindications
- Hypersensitivity to ravulizumab
- Unresolved Neisseria meningitidis infection
Common side effects
- Headache
- Nasopharyngitis
- Upper respiratory tract infection
- Diarrhoea
- Fatigue
Counselling Points
- Vaccination against meningococcal infection required
- Monitor for signs of infection
- Inform about potential infusion reactions
Serious warnings
- Increased susceptibility to meningococcal infections
- Serious infections with Neisseria species
Important Disclaimer
The Ultomiris 300 & 1100 Mg 300 mg, 1100 mg Concentrate for solution for infusion professional information leaflet below is the property of Astrazeneca Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
